Advancing Cancer and Infectious Disease Treatment with PDS Biotechnology ($PDSB: NASDAQ)
PDS Biotechnology Corporation (NASDAQ: PDSB) is pioneering advancements in immunotherapy, focusing on harnessing the body's immune system to combat cancer and infectious diseases. With its proprietary Versamune® platform, PDS Biotech is developing targeted treatments that stimulate potent T cell responses, aiming to improve patient outcomes and redefine therapeutic approaches.
LATEST NEWS
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
The PDS Biotech Vision: Revolutionizing Immunotherapy
PDS Biotech is at the forefront of developing precision immunotherapies that enhance the body’s ability to fight cancer and infectious diseases. Traditional treatments such as chemotherapy and radiation can come with severe side effects and limited long-term efficacy. PDS Biotech’s approach is different—it utilizes its proprietary Versamune® and Infectimune® platforms to deliver safer, more effective immunotherapies that activate strong and lasting immune responses.
By leveraging innovative technology and strategic partnerships, PDS Biotech is positioning itself as a leader in next-generation immunotherapies, focusing on both oncology and infectious disease prevention.
PDS Biotechnology Corporation
(NASDAQ: PDSB)
Versamune®: Unlocking the Power of T Cell Therapy
The Versamune® platform is designed to drive potent, antigen-specific T-cell responses against cancer-associated targets. Unlike checkpoint-only immunotherapies, Versamune® actively programs tumor-specific killer T cells and is intended to work synergistically with other immune-modulating agents to improve anti-tumor activity.
Preclinical and clinical studies have demonstrated robust immune activation and durable clinical benefit, supporting advancement into late-stage clinical development. With its lead program now in Phase 3, Versamune® represents a focused effort to translate targeted immune activation into meaningful outcomes for patients with HPV-driven cancers.
Infectimune®: Immune Activation Beyond Oncology
PDS Biotech’s Infectimune® platform applies similar immune-programming principles to the development of next-generation infectious disease vaccines. The company’s universal influenza vaccine candidate, PDS0202, has demonstrated broad and durable immune responses in preclinical models, supporting its potential as a long-term vaccine platform.
While still in preclinical development, Infectimune® provides future optionality by leveraging antigen-specific immune activation strategies that may be applicable across multiple infectious disease targets.
The point of using dummy text for your paragraph is that it has a more-or-less normal distribution of letters. making it look like readable English.
PDS Biotechnology Corporation
(NASDAQ: PDSB)
Strategic Collaborations Driving Innovation
PDS Biotech conducts its clinical programs in collaboration with leading academic cancer centers and government-supported research organizations, including the National Cancer Institute and major oncology trial sites such as Mayo Clinic. These collaborations support rigorous trial execution, independent data generation, and translational research, reinforcing the scientific credibility of the company’s immunotherapy programs.
Through these clinical engagements, PDS Biotech continues to refine its therapeutic approaches and generate data to support late-stage development, positioning the company as a serious participant in the evolving immunotherapy landscape.
Disciplined Growth Strategy Focused on Clinical Execution
As PDS Biotech advances its oncology and vaccine pipeline, the company remains focused on executing defined clinical milestones, particularly completion of its ongoing Phase 3 program. Its strategy emphasizes data-driven refinement of therapeutic approaches and alignment with future regulatory pathways, rather than premature commercial expansion.
This disciplined approach allows the company to concentrate resources on its most value-defining programs while maintaining optionality for future growth.
Long-Term Potential in Immunotherapy Innovation
With two differentiated immunotherapy platforms in the works: Versamune® and Infectimune®. They are Designed to activate antigen-specific immune responses across oncology and infectious disease applications. While still a clinical-stage company, its expanding pipeline and late-stage program position it to potentially contribute meaningfully to next-generation immune-based therapies.
As global interest in immunotherapy and advanced vaccines continues to grow, PDS Biotech’s platforms represent long-term potential, contingent on successful clinical outcomes and regulatory progress.
Meet the PDS Biotechnology Team
(NASDAQ: PDSB)
Frank Bedu-Addo, Ph.D. | CEO, Director
Dr. Bedu-Addo has served as a director, president and CEO of PDS Biotech since its inception in 2005. Dr. Bedu-Addo is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations and emerging biotechnology companies.
Stephen Toutain | Chief Operating Officer
Stephan Toutain, MS, MBA, joined PDS Biotech in May 2024 as Chief Operating Officer (COO). He brings over 30 years of operational experience in the life sciences industry from drug development, general management, operations, commercial development, market access and sales and marketing leadership with prior expertise in oncology and orphan drugs markets globally.
Lars Boesgaard | Chief Financial Officer
Mr. Boesgaard joined PDS Biotech in December 2023 as its Chief Financial Officer. Mr. Boesgaard has had a career spanning more than 25 years in healthcare and has deep capital markets and investor relations experience with global clinical and commercial-stage pharmaceutical and biotechnology companies.
Gregory Conn | Chief Scientific Officer
Dr. Conn has more than 35 years of drug-development expertise, including development of antiviral and anticancer drugs through to commercialization. He is a graduate of the Albert Einstein College of Medicine, where he obtained both his M.S. and Ph.D., discovering novel angiogenic molecules in the human brain.
Sources
- https://finance.yahoo.com/quote/PDSB/
- https://pdsbiotech.com/index.php/science/overview
- https://pdsbiotech.com/index.php/about/about-us
- https://pdsbiotech.com/
- https://pdsbiotech.com/index.php/pipeline/oncology-page
- https://pdsbiotech.com/index.php/investors
- https://pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/132-2025-news/968-iotecheaffirmsuidanceforirstuarternitiation20250205
Disclaimer
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Compensation: Pursuant to an agreement between Virtus Media Group LLC and PDS Biotechnology, Virtus Media Group been paid $35,000 USD to publicly disseminate information about NASDAQ: PDSB via digital communications beginning 2026-1-7 and ending 2026-1-8. We have paid The Investing Authority $7,500 USD Influencer compensation: Social media influencer #1 has been paid $15,000 USD to publicly disseminate information about NASDAQ: PDSB via digital communications. Pursuant to an agreement between JRZ Capital and Virtus Media Group LLC, Virtus Media Group has been hired to publicly disseminate information about NASDAQ: PDSB via digial communications on 2/18 only. Virtus Media Group has been compensated $35,000 USD.
